In recent years, semaglutide has gained considerable attention as an innovative drug for the treatment of obesity
Secondary outcomes The secondary outcomes are as follows: type 2 diabetes, glucose, HbA1c, insulin, lipid profile (LDL-cholesterol, HDL-cholesterol, triglycerides and apolipoprotein B), systolic blood pressure, diastolic blood pressure, and body mass index (BMI), which are well-established risk factors for CVD in clinical practice, or recently identified to be related to CVD in MR, such as apolipoprotein B [30, 31]
The researchers evaluated the patient-reported outcomes of over 150 different real-world treatments to determine which interventions provided the most significant relief
Gastrointestinal side effects: Semaglutide can cause gastrointestinal side effects such as vomiting, diarrhea, and nausea that cause direct fluid loss and electrolyte imbalance, which may lead to dehydration
Ready to Add CLA to Your Routine
Monitor your progress : Keep track of your weight, dietary intake, and how you feel